

## RESEARCH ARTICLE

# Hippo signaling is required for Notch-dependent smooth muscle differentiation of neural crest

Lauren J. Manderfield<sup>1</sup>, Haig Aghajanian<sup>1</sup>, Kurt A. Engleka<sup>1</sup>, Lillian Y. Lim<sup>1</sup>, Feiyan Liu<sup>1</sup>, Rajan Jain<sup>1</sup>, Li Li<sup>1</sup>, Eric N. Olson<sup>2</sup> and Jonathan A. Epstein<sup>1,\*</sup>

## ABSTRACT

Notch signaling has well-defined roles in the assembly of arterial walls and in the development of the endothelium and smooth muscle of the vasculature. Hippo signaling regulates cellular growth in many tissues, and contributes to regulation of organ size, in addition to other functions. Here, we show that the Notch and Hippo pathways converge to regulate smooth muscle differentiation of the neural crest, which is crucial for normal development of the aortic arch arteries and cranial vasculature during embryonic development. Neural crest-specific deletion of the Hippo effectors Yap and Taz produces neural crest precursors that migrate normally, but fail to produce vascular smooth muscle, and Notch target genes such as *Jagged1* fail to activate normally. We show that Yap is normally recruited to a tissue-specific *Jagged1* enhancer by directly interacting with the Notch intracellular domain (NICD). The Yap-NICD complex is recruited to chromatin by the DNA-binding protein Rbp-J in a Tead-independent fashion. Thus, Hippo signaling can modulate Notch signaling outputs, and components of the Hippo and Notch pathways physically interact. Convergence of Hippo and Notch pathways by the mechanisms described here might be relevant for the function of these signaling cascades in many tissues and in diseases such as cancer.

**KEY WORDS:** Notch signaling, Hippo signaling, Yap, Taz, *Jagged1*, Vascular development, Neural crest, Mouse

## INTRODUCTION

The neural crest is a transient, migratory, multipotent cell population that contributes to diverse cell lineages in the developing embryo, including vascular smooth muscle. The differentiation of neural crest into vascular smooth muscle is dependent upon Notch signaling (High and Epstein, 2008). Normally, expression of the Notch ligand *Jagged1* by vascular endothelium induces Notch activation in adjacent mesenchyme, resulting in smooth muscle differentiation and transcription of Notch target genes, including *Jagged1* itself. *Jagged1* can then activate successive layers of neural crest to differentiate into smooth muscle, producing a multi-layered vascular wall (Manderfield et al., 2012). Interruption of this Notch-mediated lateral induction pathway, either by genetic deletion of *Jagged1* in endothelial cells or neural crest, or by inhibition of Notch signaling in neural crest, results in an array of aortic arch artery and smooth muscle defects (High et al., 2008, 2007).

Hippo signaling is a highly conserved kinase cascade, classically thought to regulate organ size, although its role in development and disease is rapidly expanding. The upstream Hippo kinases Mst1 and Mst2 phosphorylate kinases Lats1 and Lats2. Lats1 and Lats2 then phosphorylate the downstream effector molecules of Hippo signaling, Yap (Yap1 – Mouse Genome Informatics) and Taz. When phosphorylated, Yap and Taz are removed from the nucleus, thereby terminating transcription of Hippo target genes. Yap and Taz have no known intrinsic DNA-binding capabilities and therefore require interaction with a DNA-binding molecule to mediate their functions as co-activators. In canonical mammalian Hippo signaling, the DNA-binding moiety is one of four homologous Tead factors, but Yap and Taz can associate with numerous other transcription factors, including Pax proteins, Tbx5 and p63/p73 (Tcpl/Iap1 – Mouse Genome Informatics) (Manderfield et al., 2014; Murakami et al., 2005; Strano et al., 2001). The Hippo signaling cascade is therefore poised to integrate and modulate multiple developmental and homeostatic regulatory cascades.

Hippo signaling is crucial for vascular smooth muscle repair and development. For example, Yap expression is significantly increased in smooth muscle cells following carotid artery injury, where it promotes smooth muscle proliferation and migration (Wang et al., 2012). Although Yap and Taz are thought to mediate largely redundant functions in many tissues, deletion of *Yap* in developing smooth muscle is sufficient to disrupt smooth muscle formation, producing thin arterial walls and enlarged vessel lumens in the left carotid and thoracic arteries (Wang et al., 2014). Yap might function with Tead factors in addition to other transcriptional regulators, including myocardin, to regulate smooth muscle gene expression (Wang et al., 2014; Xie et al., 2012).

Given the diversity and breadth of cellular contexts in which Notch and Hippo signaling function in development and disease, it is not surprising that these two signaling pathways frequently intersect (High and Epstein, 2008; Heallen et al., 2011; von Gise et al., 2012; Afelik and Jensen, 2013; Gao et al., 2013; Li et al., 2009; Makita et al., 2008). For example, hepatocyte-specific *Yap* overexpression leads to an upregulation of *Notch1*, *Notch2*, *Jagged1* (*Jag1*) and the Notch target gene *Hes1* (Yimlamai et al., 2014). Evidence suggests that *Notch2* is a direct, Tead-dependent Hippo target (Yimlamai et al., 2014; Tschaharganeh et al., 2013). *Cdx2*, a transcriptional regulator of blastocyst lineage restriction, is regulated by the convergence of both Notch and Hippo signaling on a single enhancer element (Rayon et al., 2014). Genome-wide ChIP-seq for Rbp-J, the DNA-binding mediator of Notch signaling, from neuronal stem cells demonstrates Rbp-J binding throughout the *Yap* and *Tead2* loci, and that transgenic overexpression of the Notch intracellular domain (NICD) leads to increased *Yap* and *Tead2* expression (Li et al., 2012). In *Drosophila* wing imaginal disks, a complex interaction between Notch and Hippo signaling

<sup>1</sup>Department of Cell and Developmental Biology, The Cardiovascular Institute and the Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA. <sup>2</sup>Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

\*Author for correspondence (epsteinj@mail.med.upenn.edu)

has been elucidated; Notch can inhibit Yorkie (Yap)- Scalloped (Tead) complexes in a fashion dependent upon the specific ratios of Notch and Hippo signaling components (Djiane et al., 2014).

In this manuscript, we present evidence to support an additional layer of complexity in the convergence of Notch and Hippo signaling. We show that loss of *Yap* and *Taz* in neural crest abrogates Notch signaling and smooth muscle differentiation. Notch directly activates expression of *Jagged1* in neural crest (Manderfield et al., 2012). Here, we show that the *Hes1* promoter and a conserved *Jagged1* enhancer are co-activated by NICD/Rbp-J and Yap in a Tead-independent fashion. Further, we demonstrate that Yap and NICD physically interact. The convergence of Notch and Hippo signaling on a common transcriptional complex might have relevance to the understanding of how these pathways co-regulate many aspects of organogenesis, regeneration and cancer.

## RESULTS

Using *Wnt1-Cre*, we have previously shown that genetic deletion of *Yap* and *Taz* in premigratory neural crest results in embryonic lethality associated with craniofacial defects and vascular hemorrhages (Manderfield et al., 2014). This is a more dramatic phenotype than the previously reported *Yap* deletion in smooth muscle, which resulted in only arterial dilation (Wang et al., 2014). Further examination of E10.5 embryos in which *Yap* and *Taz* have both been deleted in neural crest, and that also express a Td/tomato reporter allele, demonstrates normal migration and patterning of cardiac neural crest (Fig. 1; supplementary material Fig. S1). Neural crest derivatives surround sections of the brachial arch arteries and the outflow tract of the heart in both control and mutant embryos. However, smooth muscle differentiation of neural crest, as determined by expression of SM22 $\alpha$  (Tagln – Mouse Genome Informatics) (Fig. 1), SMA (Acta2 – Mouse Genome Informatics), desmin (Des) or smooth muscle myosin (Fig. 2), is absent in mutant embryos. This defect is in striking contrast to the ability of non-neural crest-derived mesenchyme, which forms some of the vascular smooth muscle of the third aortic arch artery, to differentiate normally (Figs 1 and 2). Both neural crest and


non-neural crest mesenchyme surrounding the third aortic arch artery express nuclear Yap, with low levels of phosphorylated Yap (pYap) largely confined to the inner endothelial layer (Fig. 3).

Equivalent numbers of migratory RFP<sup>+</sup> control or RFP<sup>+</sup> Yap/Taz null neural crest cells surround the third arch artery (118.9 $\pm$ 12.1 control versus 121.0 $\pm$ 13.9 null. (See Materials and Methods for quantification methods.) Both samples exhibit similar proliferation rates (2.6% control versus 1.9% null; supplementary material Fig. S2), supporting the notion that the observed smooth muscle phenotype is a result of impaired differentiation.

Notch activation and *Jagged1* expression are required for proper differentiation of neural crest into smooth muscle and for expression of SM22 $\alpha$  and SMA (High et al., 2008, 2007). Loss of Yap/Taz in neural crest results in a dramatic decrease in *Jagged1* and NICD expression in mesenchyme surrounding the third aortic arch artery in a region normally populated by neural crest, while endothelial NICD expression is intact (Fig. 4A–D,E–H).


In order to explore further the effects on Notch signaling resulting from loss of Yap/Taz, we generated murine embryonic fibroblasts (MEFs) from *Taz*<sup>flox/flox</sup>; *Yap*<sup>flox/flox</sup> embryos. Treatment with adenovirus expressing Cre recombinase results in efficient deletion of Yap and Taz protein (Fig. 4I). In MEFs, deletion of Yap and Taz produces a significant decrease in both *Jagged1* and *Hrt3* (*Heyl* – Mouse Genome Informatics) expression. *c-myc* (*Myc*), a known Notch and Hippo target (Weng et al., 2006; Neto-Silva et al., 2010), is also significantly decreased (Fig. 4J).

*Hes1* is a canonical, direct target of Notch signaling, and an Rbp-J-dependent Notch-responsive *Hes1* regulatory element located –194 to +160 relative to the *Hes1* transcriptional start site has been previously characterized (Jarriault et al., 1995). We verified that NICD activates a reporter construct containing this *Hes1* enhancer (Fig. 5A). Interestingly, NICD activation of this *Hes1* reporter is significantly enhanced by the addition of Yap (Fig. 5A). Surprisingly, the activation induced by Yap and NICD is unaffected by co-transfection of a dominant-negative form of Tead (Dntead1) (Fig. 5A), although Dntead1 is able to potentially inhibit Yap activation of a control reporter construct containing




**Fig. 1. Deletion of Yap and Taz in neural crest results in impaired smooth muscle differentiation.** (A) *Wnt1-Cre; Taz*<sup>flox/+</sup>; *Yap*<sup>flox/+</sup>; *R26*<sup>Tomato/+</sup> E10.5 embryo imaged in bright-field and fluorescence. (B–H) Transverse sections of E10.5 *Wnt1-Cre; Taz*<sup>flox/+</sup>; *Yap*<sup>flox/+</sup>; *R26*<sup>Tomato/+</sup> embryos stained for tdTomato (RFP) and SM22 $\alpha$ . (I) *Wnt1-Cre; Taz*<sup>flox/flox</sup>; *Yap*<sup>flox/flox</sup>; *R26*<sup>Tomato/+</sup> embryo imaged in bright-field and fluorescence. (J–P) Transverse sections of E10.5 *Wnt1-Cre; Taz*<sup>flox/flox</sup>; *Yap*<sup>flox/flox</sup>; *R26*<sup>Tomato/+</sup> embryos stained for tdTomato (RFP) and SM22 $\alpha$ . Arrowheads denote sites of decreased smooth muscle differentiation. Branchial arches (ba) are invested with red-fluorescing Wnt1-derived neural crest (A, I). iii, third aortic arch artery; Ao, aortic sac. Images in B, E, H, J, M, P were merged by combining respective red and green channels using Photoshop software (Adobe). Scale bars: 100  $\mu$ m.





**Fig. 2. Deletion of Yap and Taz in neural crest results in impaired smooth muscle expression.** (A–I) Transverse sections of E10.5 *Wnt1-Cre; Taz<sup>flox/+</sup>; Yap<sup>flox/+</sup>; R26<sup>Tomato/+</sup>* embryos stained for tdTomato (RFP, A), SMA (B), merged RFP/SMA (C), tdTomato (RFP, D), desmin (E) or merged RFP/desmin (F). Yellow arrows denote RFP/desmin double-positive cells. Serial sections stained for tdTomato and Hoechst (RFP, G), smMyosin (H) or smMyosin and Hoechst (I). White arrows denote presumptive RFP/smMyosin double-positive cells. (J–R) Transverse sections of E10.5 *Wnt1-Cre; Taz<sup>flox/flox</sup>; Yap<sup>flox/flox</sup>; R26<sup>Tomato/+</sup>* embryos stained for tdTomato (RFP, J), SMA (K), merged RFP/SMA (L), tdTomato (RFP, M), desmin (N) or merged RFP/desmin (O). Serial sections stained for tdTomato and Hoechst (RFP, P), smMyosin (Q) or smMyosin and Hoechst (R). White arrows highlight RFP<sup>+</sup>, smMyosin<sup>+</sup> cells. Merged images were generated by combining respective red and green channels using Photoshop (C,F,L,O). iii, third aortic arch artery. Scale bars: 100  $\mu$ m.

Tead binding sites (Fig. 5B). Previously, we identified a 617-bp conserved, Notch-responsive intronic enhancer that regulates *Jagged1* expression in cardiac neural crest, which we have termed Jagged1-ECR6 (Manderfield et al., 2012). As previously reported, NICD activates a reporter construct containing Jagged1-ECR6 upstream of a synthetic minimal promoter driving luciferase expression. Interestingly, Yap is also able to activate this reporter, and the combination of NICD and Yap generates significantly more activity than either NICD or Yap alone (Fig. 5C). As with *Hes1*, ECR6 activation induced by Yap, or Yap with NICD, is unaffected by Dntead1 (Fig. 5C). This result suggests that Yap-mediated activation of ECR6 is Tead-independent. Yap/Taz activity is regulated, at least in part, by the Hippo kinase cascade (Mst and




**Fig. 3. Mesenchyme adjacent the third aortic arch artery expresses Yap.** (A–E) Transverse sections of wild-type E10.5 embryos stained for Yap (A), Yap, eNOS and Hoechst (B), phospho-Yap (pYap, C), pYap, eNOS and Hoechst (D), pYap and Hoechst (E) or eNOS and Hoechst (F). White arrows denote pYap/eNOS double-positive cells. The boxed area in D is shown at higher magnification with single stains in E,F. iii, third aortic arch artery. Scale bars: 100  $\mu$ m in A–D; 20  $\mu$ m in E,F.

Lats), which ultimately control Yap/Taz nuclear localization. As expected, co-transfection of a construct encoding Mst1 abrogates the ability of Yap to activate ECR6, either alone or in combination with NICD (Fig. 5D). A kinase-inactive form of Mst1 failed to inhibit Yap-mediated activation.

Chromatin immunoprecipitation (ChIP) experiments suggest that both NICD and Yap occupy ECR6 (Fig. 6A). ChIP with antibodies specific for NICD or Yap produce ~10-fold enrichment of ECR6 compared with control IgG. No enrichment was detected for a distant upstream *Jagged1* conserved putative enhancer, previously termed ECR1, which is 456 bp and not activated by Notch (Manderfield et al., 2012). Importantly, both NICD and Yap occupancy are completely abrogated by mutation of the single Rbp-J binding site located within ECR6, denoted ECR6\* (Manderfield et al., 2012). This result suggests that Rbp-J binding is required for recruitment of both NICD and Yap to the *Jagged1* enhancer. Accordingly, the presence of the Rbp-J mutation prevented NICD-Yap co-activation of ECR6 in a luciferase assay (Fig. 6B). Co-immunoprecipitation (Co-IP) experiments revealed that NICD and Yap can physically interact (Fig. 6C), supporting the idea that Yap can function as a Notch co-activator.

MDA-MB-231 breast carcinoma cells express NICD and Yap (Yu et al., 2013; Stylianou et al., 2006). ChIP for endogenous Yap in these cells revealed co-occupancy of the endogenous *Hes1* promoter and *Jagged1* ECR6 enhancer, but again not of the adjacent genomic region denoted by ECR1 that is not regulated by Notch (Fig. 6D).

We next examined the role of the NICD-Yap complex in MOVAS cells, a mouse aortic smooth muscle cell line. RT-PCR analysis confirmed that this cell line expresses the NICD-Yap target genes *Jag1* and *Hes1*, and smooth muscle genes, including *Tagln*, *Acta2*, *Des1* (*Des* – Mouse Genome Informatics) and *Cnn1* (Fig. 7A). Treatment with the  $\gamma$ -secretase inhibitor DAPT (100  $\mu$ M) resulted in a dramatic decrease in *Jag1* and *Hes1* expression, consistent with both genes being Notch signaling targets (Fig. 7B). Overexpression of the upstream Hippo kinase Lats2 led to a robust increase in Yap phosphorylation (pYap) (Fig. 7C), which will remove Yap from the nucleus. The presence of Lats2 inhibited *Jag1* and *Hes1* expression as well as expression of smooth muscle genes *Acta2*, *Cnn1* and *Des1* (Fig. 7D). *Hrt1* and *Hrt2*, two genes unchanged following




**Fig. 4. Decreased Notch activity following Yap/Taz deletion.** (A-D) Transverse sections of E10.5 *Taz<sup>flox/flox</sup>;Yap<sup>flox/flox</sup>* embryos immunostained for Jagged1 (A), Jagged1 with eNOS (B), NICD (C) or NICD with eNOS (D). (E-H) Transverse sections of E10.5 *Wnt1-Cre; Taz<sup>flox/flox</sup>;Yap<sup>flox/flox</sup>* embryos immunostained for Jagged1 (E), Jagged1 with eNOS (F), NICD (G) or NICD with eNOS (H). (I) Anti-Yap and anti-Taz immunoblots from *Taz<sup>flox/flox</sup>;Yap<sup>flox/flox</sup>* MEFs untreated (0) or treated with increasing AAV-CMV-Cre doses [500 genome copies per cell (GC), 1000 GC or 2000 GC]. In parallel, immunoblots of the same protein lysates were probed with anti-actin to demonstrate equivalent protein loading. (J) qRT-PCR of untreated or AAV-CMV-Cre virus-treated (1000 GC) *Taz<sup>flox/flox</sup>;Yap<sup>flox/flox</sup>* MEFs for *c-myc*, *Hrt1*, *Hrt2*, *Hrt3* and *Jagged1*. Data depicted in J are mean+s.e.m. Statistics were completed using Student's t-test. \*\**P*<0.01, \*\*\**P*<0.001. iii, third aortic arch artery. Scale bars: 100  $\mu$ m.

Yap/Taz deletion in MEFs (Fig. 4J), were similarly unchanged following *Lats2* expression in MOVAS cells (Fig. 7D). Co-IP experiments confirm that NICD and Yap can physically interact in MOVAS smooth muscle cells (Fig. 7E). ChIP with native antibodies specific for endogenous Yap or NICD demonstrate specific recruitment and enhanced occupancy to both the endogenous ECR6 enhancer and the endogenous *Hes1* promoter compared with ECR1, a distant upstream *Jagged1* conserved region (Fig. 7F).


The Yap protein contains well-defined structural domains, including an N-terminal Tead-binding domain, a C-terminal

transactivation domain and two WW domains (Varelas, 2014). WW domains mediate protein-protein interactions with proline-rich or proline-containing motifs. High-affinity binding occurs with proteins containing a PPxY motif, and lower-affinity interactions have been identified with proteins containing PPLP or PPR motifs (where P is a proline residue, Y is a tryptophan residue, L is an leucine residue, R is an arginine residue and x stands for any amino acid) (Varelas, 2014; Russ et al., 2005). Yap interaction with Tead factors is mediated by the N-terminal Tead interaction domain, but Yap can interact with other DNA-binding proteins in a manner



**Fig. 5. NICD transcriptional activity is increased in the presence of Yap and the activation is Tead1 independent.** Results of dual luciferase reporter assays in HEK293T cells are shown. (A) *Hes1* reporter assay in the presence (+) or absence (-) of NICD, Yap or Dntead1, *n*=3. Complete ANOVA results are included in supplementary material Table S1. (B) 8 $\times$  GTTTC-Tead-reporter luciferase assay in the presence (+) or absence (-) of Yap or Dntead1, *n*=3. (C) Jagged1 enhancer element (ECR6)-luciferase reporter assay in the presence (+) or absence (-) of NICD, Yap or Dntead1, *n*=3. Complete ANOVA results are included in supplementary material Table S2. (D) ECR6-luciferase reporter assay in the presence (+) or absence (-) of NICD, Yap, Mst1 or a kinase-inactive form of Mst1, Mst1-KI, *n*=4. Complete ANOVA results are included in supplementary material Table S3. All experiments were performed in duplicate for a minimum of three individual occasions, with specific replicate numbers shown in each legend. Data depicted are mean+s.e.m. Statistics were completed using ANOVA with a Tukey-Kramer post-hoc comparison test. \*\*\**P*<0.001, \*\**P*<0.01, \**P*<0.05.





**Fig. 6. NICD and Yap specifically co-occupy *Jagged1* ECR6 and physically interact.** (A) Chromatin immunoprecipitation (ChIP) for NICD (FLAG) or Yap from cells transfected with a 3× FLAG-tagged NICD construct, a Yap expression construct and either an ECR1 expression plasmid, an ECR6 expression plasmid or a mutant ECR6 expression plasmid (ECR6\*). Data are reported as fold enrichment over an IgG ChIP performed in parallel with the same samples. (B) Results of dual luciferase reporter assays in HEK293T cells with a *Jagged1* enhancer element (ECR6), using either a wild-type ECR6-luciferase reporter or a mutant ECR6-luciferase reporter (ECR6\* reporter) with a mutated Rbp-J binding site in the presence (+) or absence (-) of NICD or Yap,  $n=3$ . (C) Western blots demonstrating co-immunoprecipitation of Yap and NICD. Lysates were immunoprecipitated with either a control IgG or FLAG antibody in the presence (+) or absence (-) of Yap and NICD. The Yap construct contains an N-terminal FLAG epitope tag. The NICD construct contains a C-terminal V5 epitope tag. Input immunoblots confirmed NICD (V5) and Yap (FLAG) expression in specified samples.  $\beta$ -actin immunoblot confirmed protein expression in all samples. (D) ChIP for endogenous Yap from non-transfected MDA-MB-231 cells at *Jagged1* genomic loci, ECR1 and ECR6, and the *Hes1* promoter. Data are reported as fold enrichment over an IgG ChIP performed in parallel with the same samples. Dual luciferase experiments were performed in duplicate for a minimum of three individual occasions. ChIP experiments were also completed in biological triplicate. Data depicted are mean±s.e.m. Statistics were completed using ANOVA with a Tukey–Kramer post-hoc comparison test. \*\*\* $P<0.001$ , \*\* $P<0.01$ , \* $P<0.05$ .


dependent upon the WW domains (Zhao et al., 2009). Murine NICD1 has amino acid sequences similar to two of the lower-affinity proline-containing motifs, PPLLP and PPPPR. Mutation of the first Yap WW domain, but not the second WW domain, prevented Yap from augmenting NICD induction of *Jagged1*-ECR6 (Fig. 8A). As previously reported, none of the Yap WW domain mutants prevented activation of a Tead-dependent reporter (Fig. 8B) (Zhao et al., 2009), and immunoblot analysis confirmed that wild-type and mutant Yap constructs were expressed at similar protein levels (Fig. 8C). We confirmed that NICD could interact with Yap by using the Duolink proximity ligation assay to monitor protein-protein interactions *in situ* and found that mutation of the first Yap WW domain, but not of the second WW domain, prevented Yap interaction with NICD (Fig. 8D). Taken together, these results suggest that Yap can interact with NICD by utilizing the first WW domain, and that Yap and NICD can be recruited to the *Jagged1* enhancer by the DNA-binding protein Rbp-J.

## DISCUSSION

In this study, we demonstrate a crucial role for Hippo signaling in the differentiation of neural crest-derived smooth muscle. We show that deletion of the Hippo effector molecules Yap and Taz in neural crest disrupts Notch signaling, and we provide evidence that Yap can physically and functionally interact with NICD to augment transcription in a manner that is independent of Tead factors.

We have focused on the ability of a Yap-NICD-Rbp-J complex to regulate *Jagged1*. However, it is unlikely that all NICD/Rbp-J targets require Yap as a co-factor, and we note that Yap/Taz deletion did not alter expression of several Notch target genes, including *Hrt1* and *Hrt2* in MEFs (Fig. 4J). Moreover, many aspects of Hippo signaling and Yap function are almost certainly Notch independent. Consistent with this conclusion, loss of Yap and Taz in neural crest is embryonic lethal at E10.5, whereas loss of Notch signaling (via expression of a dominant negative mastermind protein or via deletion of Rbp-J) causes a less-severe phenotype, although all exhibit defective smooth muscle differentiation (High et al., 2007; Mead and Yutzey, 2012). Particularly striking is the similarity of the smooth muscle defect in animals in which either Yap/Taz or Rbp-J are deleted in neural crest (Mead and Yutzey, 2012). In both models, neural crest cells migrate to the aortic arch arteries, yet are unable to differentiate to smooth muscle, in contrast to the non-neural crest-derived cells surrounding each arch (Mead and Yutzey, 2012). The likeness of these models supports our findings that Yap could function as a necessary co-factor for the NICD-Rbp-J complex. In the future, it would be interesting to compare ChIP-seq analyses of Yap, Tead, Rbp-J and NICD in neural crest, although the limited material available from microdissected or sorted embryonic tissue will make this approach highly technically challenging at present.

The identification of a Yap-NICD-Rbp-J complex might lead to the re-interpretation of many Hippo signaling phenotypes.



**Fig. 7. NICD and Yap interact and modulate transcription in smooth muscle cells.** (A) RT-PCR from three biological replicates of MOVAS cells. (B) qRT-PCR of vehicle (DMSO)- or DAPT (100  $\mu$ M)-treated MOVAS cells. Data depicted are mean+s.e.m. and the statistics were completed using Student's *t*-test; \*\*\**P*<0.001. (C) Anti-myc (Lats2) and anti-pYap immunoblots from MOVAS cells transfected with increasing amounts of myc-tagged Lats2. In parallel, immunoblots of the same protein lysates were probed with anti-actin to demonstrate equivalent protein loading. (D) qRT-PCR of non-transfected (NT) or Lats2 (2  $\mu$ g)-transfected MOVAS cells. Data depicted are mean+s.e.m. and the statistics were completed using Student's *t*-test; \**P*<0.05. (E) Western blot demonstrating co-immunoprecipitation of Yap and NICD in MOVAS cells. Lysates were immunoprecipitated with either a control IgG or NICD antibody. Input immunoblots confirmed NICD and Yap expression. (F) ChIP for endogenous Yap and NICD in non-transfected MOVAS cells at *Jagged1* genomic loci, ECR1 and ECR6, and the *Hes1* promoter. Data are reported as fold enrichment over an IgG ChIP performed in parallel with the same samples. Data depicted are mean+s.e.m. The statistics were completed using Student's *t*-test; \*\**P*<0.01, \**P*<0.05. qRT-PCR and ChIP experiments were completed in biological triplicate.

Modulation of Hippo signaling has frequently been reported to result in alterations of Notch target gene expression. For example, genetic deletion of *Mst1/2* in pancreatic epithelium resulted in increased Yap expression and a robust increase in *Hes1* expression (Gao et al., 2013). Yap overexpression in hepatocytes caused upregulation of *Notch1/2*, *Jagged1*, *Hes1* and the Notch target *Sox9* (Yimlamai et al., 2014). Furthermore, recent studies demonstrated that an interleukin-6 co-receptor, gp130 (Il6st – Mouse Genome Informatics), can activate both Hippo and Notch signaling (Taniguchi et al., 2015). This work was interpreted in terms of parallel Hippo and Notch signaling pathways. In light of our results, it would be interesting to revisit these and other prior studies to determine whether a Yap-NICD-Rbp-J complex is contributory.

Hippo signaling has been studied extensively in the context of its ability to regulate organ size and, more recently, with a focus on epithelial-mesenchymal transformation and cancer. However, relatively little work has implicated Hippo in regulation of cell

fate or differentiation. Recently, Hippo has been implicated in maintenance of the differentiated hepatocyte fate, and disruption of Hippo resulted in hepatocyte dedifferentiation to a multi-potent progenitor state. Intriguingly, these studies also suggested that Notch signaling was functional downstream of Yap in this setting, although the potential role of a Yap-NICD complex was not examined (Yimlamai et al., 2014).

The identification of a Yap-NICD complex might be particularly important in the understanding of tumor biology. Reactivation of either Notch or Hippo signaling has been implicated in various cancers (Mo et al., 2014; Andersson and Lendahl, 2014). In hepatocellular carcinomas, studies have identified a robust increase in Yap expression, which can increase proliferation and tumor progression (Zender et al., 2006). Subsequently, in a human hepatocellular carcinoma cell line, Yap overexpression has been shown to increase *Jagged1* expression through an upstream Tead-dependent enhancer (Tschaharganeh et al., 2013). Interestingly, this study also examined a region of the *Jagged1* locus, which includes *Jagged1*-ECR6, and observed no Tead-Yap-dependent activation, supporting our results that *Jagged1*-ECR6 activation is Tead independent (Tschaharganeh et al., 2013). Transgenic overexpression of NICD in hepatoblasts also resulted in hepatocellular carcinoma, and further analysis of human hepatocellular carcinoma samples demonstrated that a reactivation of the Notch pathway occurs frequently in these tumors (Villanueva et al., 2012). A similar reactivation of Notch and Hippo signaling has also been observed in breast cancers (Li et al., 2015; Robinson et al., 2011). It will be of interest to determine whether Hippo and Notch functionally interact to promote cancer progression at least in part by activating downstream genes that are regulated by a Yap-NICD-Rbp-J complex.

## MATERIALS AND METHODS

### Mice


All mice were maintained on a mixed genetic background. *Wnt1-Cre* (Jiang et al., 2000), *Yap<sup>fllox/+</sup>* (Xin et al., 2011) and *Taz<sup>fllox/+</sup>* (Xin et al., 2013) alleles were genotyped as previously described. *R26tdTomato* mice [B6.Cg-Gt(*ROSA*)26Sortm14(*CAG-tdTomato*)Hze/J] were obtained from Jackson Labs (strain number 007914) and genotyped as previously described (Madisen et al., 2010). All animal protocols were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.

### Plasmids

The firefly-luciferase reporter construct *Jagged1*-ECR6 (chr2:136933719–136934335, mm10) was generated previously (Manderfield et al., 2012) but subcloned into pGL4.27 (Promega). The *Jagged1*-ECR6-mutant construct, abbreviated ECR6\*, which contains an altered Rbp-J binding site from 5'-TTTCCACAGT-3' to 5'-TGCAGCACAGT-3', was previously described (Manderfield et al., 2012). The *Hes1* firefly-luciferase reporter construct was previously described (High et al., 2007). Murine cleaved notch intracellular domain (NICD) with a C-terminal 3 $\times$  FLAG epitope tag, and murine Rbp-J with an N-terminal 6 $\times$  c-myc epitope tag were described previously (Manderfield et al., 2012). We PCR-generated and sequence-verified a murine NICD with a C-terminal V5 epitope tag for biochemical experiments. The Tead reporter, 8 $\times$  GTTIC, murine *Yap*, *Dntead1*, murine Hippo kinases *Mst1* and *Mst1-KI*, and human Hippo kinase *LATS2* were all described previously (Manderfield et al., 2014). Wild-type human *YAP2*, as well as human *YAP2* mutants, *YAP2-WW1* (W199A, P202A), *YAP2-WW2* (W258A, P261A) and *YAP2-WW1WW2* (W199A, P202A, W258A, P261A), were previously described and contain two N-terminal FLAG epitope tags [Oka et al. (2008); Addgene plasmids 19045, 19046, 19047 and 19048].

### Cell culture and luciferase assay

HEK293T cells were maintained at 37°C with 5% CO<sub>2</sub> in DMEM supplemented with 10% fetal bovine serum, penicillin and streptomycin.



**Fig. 8. NICD-Yap interaction requires the first Yap WW domain.** (A) Results of dual luciferase reporter assays in HEK293T cells with an ECR6-luciferase reporter in the presence (+) or absence (–) of NICD, Yap or Yap mutants, Yap-WW1, Yap-WW2 or Yap-WW1WW2,  $n=4$ . Complete ANOVA results are included in supplementary material Table S4. (B) Results of dual luciferase reporter assays in HEK293T cells with 8× GT1C-Tead luciferase reporter in the presence (+) or absence (–) of Yap or Yap mutants, Yap-WW1, Yap-WW2 or Yap-WW1WW2,  $n=3$ . (C) Anti-FLAG and anti-Yap immunoblots from HEK293T cells transfected with FLAG-tagged Yap or FLAG-tagged Yap mutants. (D) Examination of NICD-Yap interaction using Duolink reagents. Interaction is documented as red fluorescence. Samples were co-transfected in the presence (+) or absence (–) of the specified plasmids. NICD-V5+Rbp-J served as positive control. The samples in the bottom row were not transfected with NICD-V5, but did include the V5 antibody to serve as negative controls. Scale bars: 100  $\mu$ m. Dual luciferase experiments were performed in duplicate for a minimum of three individual occasions. Data depicted are mean $\pm$ s.e.m. Statistics were completed using ANOVA with a Tukey–Kramer post-hoc comparison test. \*\*\* $P<0.001$ , \*\* $P<0.01$ .

Human breast adenocarcinoma MDA-MB-231 cells, used for endogenous ChIP in Fig. 6D, were maintained at 37°C with 5% CO<sub>2</sub> in Leibovitz's L-15 media supplemented with 15% fetal bovine serum, penicillin and streptomycin. MOVAS cells, used in the entirety of Fig. 7, were maintained at 37°C with 5% CO<sub>2</sub> in DMEM supplemented with 10% fetal bovine serum, penicillin and streptomycin and were given a dose of 0.2 mg/ml G-418 every 10 passages, per supplier's instructions (American Type Culture Collection, #CRL-2797). MOVAS cells were treated with either vehicle (DMSO) or 100  $\mu$ M DAPT (Sigma-Aldrich, # D5942) for 48 h. All transfections in all cell types were prepared using FuGene6 (Promega). Experiments included 300 ng of the specified firefly-luciferase reporter constructs, 80 ng *Yap*, 300 ng NICD expression vector and 75 ng pGL2-Basic-renilla luciferase (Promega). In experiments in which the Hippo kinases *Mst1* or *Mst1-KI* were co-expressed, 120 ng of the designated expression vector was included. All transfections maintained an equal concentration of total DNA with the inclusion of the pCMV-Sport6 empty vector (Invitrogen). Cellular extracts were collected 48 h post-transfection and measured in a dual-luciferase assay (Promega) in which the cellular extract was used to assess firefly and renilla luciferase activities. All luciferase activity measurements were normalized to the

renilla activity of each sample. All experiments were performed in duplicate on at least three separate occasions. Statistical differences between conditions were analyzed using ANOVA, with a Tukey–Kramer post-hoc comparison test.

#### Histology, immunofluorescence and *in situ* hybridization

Samples were harvested, fixed overnight in 4% paraformaldehyde and dehydrated through an ethanol series. All samples were paraffin-embedded and sectioned. All primary antibodies were incubated overnight at 4°C at the specified dilutions. Antibodies used for immunofluorescence were anti-SM22 $\alpha$  (1:100; Abcam, #10135), anti-RFP (1:50; Rockland Immunochemicals, #600-401-379), anti-SMA (1:200; Sigma-Aldrich, #A2547), anti-desmin (1:20; Dako, #M0760, Clone D33), anti-smooth muscle myosin heavy chain (smMyosin, 1:100; Thomas Scientific, #BT-562), anti-Yap (1:200; Cell Signaling, #4912S), anti-phospho Yap (1:200; Cell Signaling, MA, #4911), anti-Jagged1 (1:25; Santa Cruz Biotechnology, sc-8303), anti-eNOS (1:250; BD Biosciences, #610296) and anti-NICD (1:25; Cell Signaling, #2421). Hoechst nuclear counterstaining was completed following a standard protocol.



### Mouse embryo fibroblast preparation

Mouse embryo fibroblasts (MEFs) were isolated from E14.5 *Taz<sup>flx/flx</sup>; Yap<sup>flx/flx</sup>* embryos as described (Connor, 2001). To delete the floxed *Taz* and *Yap* alleles, MEFs were treated for 48 h with an adeno-associated virus expressing a constitutively active Cre-recombinase (AAV1-CMV-Cre, Penn Vector Core, University of Pennsylvania, Philadelphia, PA, USA). Viral treatment is reported as genome copies (GC) per cell.

### RNA isolation, complementary DNA synthesis and quantitative real-time PCR

RNA was harvested from one 100-mm dish of untreated or AAV1-CMV-Cre-treated *Taz<sup>flx/flx</sup>; Yap<sup>flx/flx</sup>* MEFs or one well of a 6-well dish of MOVAS cells either vehicle/DAPT-treated or transfected with *LATS2* using the Qiagen RNeasy kit following manufacturer's instructions (Qiagen). Complementary DNA (cDNA) was synthesized with the Superscript III system (Invitrogen). Quantitative RT-PCR was performed in triplicate with SYBR Green reagents (Applied Biosystems). Relative gene expression was normalized to *Gapdh*. Quantitative RT-PCR primer sequences are shown in supplementary material Table S5.

### Neural crest migration and proliferation quantitation

Transverse sections from *Wnt1-Cre;Taz<sup>flx/+</sup>;Yap<sup>flx/+</sup>;R26<sup>Tom/+</sup>* and *Wnt1-Cre;Taz<sup>flx/flx</sup>;Yap<sup>flx/flx</sup>;R26<sup>Tom/+</sup>* E10.5 embryos were co-stained for RFP and phospho-histone H3 (anti-pHH3, 1:200; Cell Signaling, 9706L). ImageJ was used to calculate a total area of red cells 50  $\mu$ m from the endothelial layer of the third arch artery (247,681.7  $\mu$ m $\pm$ 25,218.7  $\mu$ m control versus 245,484.3  $\mu$ m $\pm$ 28,203.9  $\mu$ m null). Three sections from three independent embryos of each genotype were included in the analysis. ImageJ was then utilized to calculate the size of a single RFP<sup>+</sup> neural crest cell in both genotypes ( $n=34$  cells, 2082.5  $\mu$ m $\pm$ 65  $\mu$ m control versus 2029.5  $\mu$ m $\pm$ 81.7  $\mu$ m null). To calculate the number of migratory RFP<sup>+</sup> neural crest cells in both genotypes, the total red area was divided by the cell size. The number of pHH3<sup>+</sup> cells were counted by hand and the percentage of proliferative cells was determined by divided the number of pHH3<sup>+</sup> cells by the total number of RFP<sup>+</sup> cells. Data are reported as an average of each genotype  $\pm$ s.e.m. Statistical differences between conditions were analyzed using Student's *t*-test.

### Co-IP

HEK293T cells were grown to 70-90% confluency and transfected with Lipofectamine 2000 (Life Technologies, #11668019). At 48 h post-transfection, cells were collected in IP lysis buffer [50 mM Tris HCl pH 7.5, 150 mM NaCl, 1% Igepal, Calbiochem Protease Inhibitor Set I (EMD Millipore)] and sonicated on ice. Lysates were pre-cleared for 1 h at 4°C with Protein G Dynabeads (Life Technologies, #10003D). 10% of the lysates were separated for input, and equal amounts were incubated with either 5  $\mu$ g of M2 FLAG mouse monoclonal antibody (Sigma-Aldrich, #F3165) or 5  $\mu$ g of mouse IgG (Santa Cruz Biotechnology, sc-2025) for 2 h at 4°C. 20  $\mu$ l of Protein G Dynabeads were subsequently added and incubated overnight at 4°C. The beads were washed three times in 1 ml wash buffer (25 mM Tris HCl pH 7.5, 150 mM NaCl), boiled for 10 min in sample buffer [Nupage LDS sample buffer (Life Technologies), 2-mercaptoethanol, dithiothreitol] and then run on SDS-PAGE.

MOVAS cells were grown to 70-90% confluency, collected in IP lysis buffer and pre-cleared as described above. 10% of the lysates were separated for input and equal amounts were incubated with either 17 mg/ml of anti-NOTCH1 (cleaved N-terminal) rabbit polyclonal sera (Rockland Immunochemicals, #100-401-407) or equal concentration of rabbit IgG (Santa Cruz Biotechnology, sc-2027) for 2 h at 4°C. Samples were then processed as described above.

### Western blot

Protein lysates were isolated from MEFs 48 h after viral treatment. MEFs were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-base, pH 7.5, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS) plus protease inhibitors (Complete Mini, Roche) and were quantitated with a BCA Assay (Promega). Equal quantity of protein from each condition was run on a

4-12% gradient gel at 120 V for 2 h. Blots were transferred overnight at 4°C, at 20 V onto PVDF membrane (Invitrogen). Membranes were blocked in 10% non-fat dry milk/TBS-T and incubated in primary antibody overnight: anti-Yap rabbit polyclonal (Cell Signaling, #4912S; 1:1000), anti-Taz (V386) rabbit polyclonal (Cell Signaling, #4883; 1:1000) and anti- $\beta$ -actin rabbit polyclonal (Cell Signaling, #4970; 1:1000). Blots were probed with anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody (Cell Signaling) for 1 h in 5% non-fat dry milk/TBS-T and then developed using ECL Prime (Amersham).

Protein lysates were also collected from two 100-mm dishes of HEK293T cells transfected with 2  $\mu$ g of either wild-type *YAP2* or *YAP2* mutants, *YAP2-WW1*, *YAP2-WW2* and *YAP2-WW1WW2*. All *YAP2* constructs contained two N-terminal FLAG epitope tags to allow for biochemical detection. The samples were lysed in the RIPA buffer and processed exactly as described above. The primary antibodies for detection included anti-Yap rabbit polyclonal (Cell Signaling, #4912S; 1:1000), and anti-M2-FLAG mouse monoclonal (Sigma-Aldrich, #F3165; 1:2500). Blots were probed with anti-rabbit or anti-mouse HRP-conjugated secondary antibodies (Cell Signaling).

Protein lysates were collected from one well of a 6-well dish of MOVAS cells transfected with either 1  $\mu$ g or 2  $\mu$ g of *LATS2*. The *LATS2* construct contains an N-terminal myc epitope tag for biochemical detection. A non-transfected well of cells was processed in parallel as control. The samples were lysed in the RIPA buffer and processed exactly as described above. The primary antibodies for detection included anti-myc mouse monoclonal (Cell Signaling, #2276; 1:2500), anti-phospho Yap rabbit polyclonal (Cell Signaling, #4911; 1:1000) and anti- $\beta$ -actin rabbit polyclonal (Cell Signaling, #4967; 1:1000). Blots were probed with anti-rabbit or anti-mouse HRP-conjugated secondary antibodies (Cell Signaling).

Co-IP samples, both from transfected HEK293T and MOVAS cells, and input was processed as described above. The primary antibodies for detection included mouse anti-V5 mouse monoclonal (Life Technologies, #R960; 1:2500), anti-M2-FLAG mouse monoclonal (Sigma-Aldrich, #F3165; 1:2500), anti- $\beta$ -actin rabbit polyclonal (Cell Signaling, #4967; 1:1000), anti-Yap rabbit polyclonal (Cell Signaling, #4912S; 1:1000) and/or anti-NOTCH1, cleaved N-terminal (NICD, Rockland Immunochemicals, #100-401-407; 1:500). Blots were probed with anti-rabbit or anti-mouse HRP-conjugated secondary antibodies (Cell Signaling).

### Proximity ligation assay

The proximity ligation assay was performed using HEK293T cells transfected with 40 ng of the indicated cDNA, including murine NICD with a C-terminal V5 epitope tag, wild-type *YAP2*, *YAP2* mutants, *YAP2-WW1* or *YAP2-WW2* or murine Rbp-J with an N-terminal 6 $\times$  c-myc epitope tag. All transfections were completed using FuGene6 (Promega). Primary antibodies were diluted 1:200 and incubated for 1 h at room temperature; they included: anti-V5 mouse monoclonal (Life Technologies, #R960), anti-Yap rabbit polyclonal (Cell Signaling, #4912S) and anti-myc rabbit polyclonal (EMD Millipore, 06-549). Staining was performed using the Duolink *in situ* Detection Reagents Red Kit (Sigma-Aldrich) following the manufacturer's instructions. DAPI nuclear staining was included in the Duolink mounting media (Sigma-Aldrich).

### Chromatin immunoprecipitation (ChIP)

To examine NICD and Yap occupancy at Jagged1-ECR6, chromatin was generated from three 100-mm dishes of HEK293T transfected with 800 ng of the Jagged1-ECR6-pGL4.27, 100 ng of a C-terminal FLAG tagged NICD and 100 ng of a murine Yap expression plasmid. In parallel, chromatin was also isolated from cells transfected with two control conserved regions, either a distant conserved region which was not Notch responsive, Jagged1-ECR1 (chr2:136942017-136942473, mm10), or Jagged1-ECR6-mutant containing a mutated Rbp-J binding site, again both in the presence of FLAG-tagged NICD and Yap (Manderfield et al., 2012). To examine endogenous Yap and/or NICD occupancy at Jagged1-ECR6 and the *Hes1* promoter, chromatin was generated from three 100-mm dishes of non-transfected MDA-MB-231 or MOVAS cells. 48 h post-transfection, cells were washed twice in cold PBS and cross-linked with 1% formaldehyde for 10 min at room temperature. Then, the reaction was



quenched with 0.14 M glycine for 5 min at room temperature. Cells were collected in PBS, pelleted and resuspended in SDS lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, 1% NP-40, 1% SDS, 0.5% deoxycholic acid and protease inhibitors). After 10-min incubation on ice, the chromatin was sonicated using a BioRuptor (Diagenode). 10 µg of chromatin was diluted in ChIP dilution buffer (16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, 0.01% SDS, 1.1% Triton X-100) and incubated overnight at 4°C with 0.5 µg of specific antibody or control IgG: anti-Yap rabbit polyclonal (Cell Signaling, #4912S), anti-M2-FLAG mouse monoclonal (Sigma-Aldrich, #F3165), anti-NOTCH1, cleaved N-terminal (NICD, Rockland Immunochemicals, #100-401-407), normal-rabbit IgG (Santa Cruz, sc-2027) or normal-mouse IgG (Santa Cruz, sc-2025). Protein-G agarose beads were added to each reaction for 1 h at 4°C. The agarose beads were washed once with each of the following buffers for 5 min at 4°C: low salt buffer, high salt buffer, LiCl buffer and TE buffer. Complexes were eluted in 200 µl elution buffer (1% SDS, 0.1 M NaHCO<sub>3</sub>) at room temperature for 15 min. After the reversal of chromatin cross-linking, protein degradation and DNA purification, samples were PCR-amplified using primers for *Jagged1* or *Hes1* loci:

*ECR1*-Forward: 5'-TCCCAGCTCATGTATCTTTGCTTGC-3';  
*ECR1*-Reverse: 5'-GGAGGAATGCAGATCAAAGCGAAGTCT-3';  
*ECR6*-Forward: 5'-CTACAACCACTAACAGGAGAGC-3';  
*ECR6*-Reverse: 5'-GCTTCATACTTACAGCAGG-3';  
*Hes1*-Forward: 5'-TTCCTCCCATTGGCTGAAAG-3';  
*Hes1*-Reverse: 5'-AGCTCCAGATCCTGTGTGA-3'.

#### Competing interests

The authors declare no competing or financial interests.

#### Author contributions

L.J.M. designed and performed experiments, analyzed data and wrote the paper. H.A., K.A.E., L.Y.L., F.L. and L.L. designed and performed experiments. R.J. performed experiments and edited the manuscript. E.N.O. provided the Yap and Taz floxed alleles. J.A.E. oversaw the entire project, designed experiments, analyzed data and wrote the paper.

#### Funding

This work was supported by the Spain Fund for Cardiovascular Research; the Cotswold Foundation; the VVW Smith Endowed Chair; and the National Institutes of Health (NIH) [U01 HL100405 to J.A.E.]. Deposited in PMC for release after 12 months.

#### Supplementary material


Supplementary material available online at  
<http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.125807/-DC1>

#### References


- Afelik, S. and Jensen, J. (2013). Notch signaling in the pancreas: patterning and cell fate specification. *Wiley Interdiscip. Rev. Dev. Biol.* **2**, 531-544.
- Andersson, E. R. and Lendahl, U. (2014). Therapeutic modulation of Notch signalling — are we there yet? *Nat. Rev. Drug Discov.* **13**, 357-378.
- Connor, D. A. (2001). Mouse embryo fibroblast (MEF) feeder cell preparation. *Curr. Protoc. Mol. Biol.* Chapter 23:Unit 23.2.
- Dijane, A., Zaessinger, S., Babaoğlu, A. B. and Bray, S. J. (2014). Notch inhibits Yorkie activity in *Drosophila* wing discs. *PLoS ONE* **9**, e106211.
- Gao, T., Zhou, D., Yang, C., Singh, T., Penzo-Méndez, A., Maddipati, R., Tzatsos, A., Bardeesy, N., Avruch, J. and Stanger, B. Z. (2013). Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. *Gastroenterology* **144**, 1543-1553.e1.
- Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysik, E., Johnson, R. L. and Martin, J. F. (2011). Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. *Science* **332**, 458-461.
- High, F. A. and Epstein, J. A. (2008). The multifaceted role of Notch in cardiac development and disease. *Nat. Rev. Genet.* **9**, 49-61.
- High, F. A., Zhang, M., Proweller, A., Tu, L., Parmacek, M. S., Pear, W. S. and Epstein, J. A. (2007). An essential role for Notch in neural crest during cardiovascular development and smooth muscle differentiation. *J. Clin. Invest.* **117**, 353-363.
- High, F. A., Lu, M. M., Pear, W. S., Loomes, K. M., Kaestner, K. H. and Epstein, J. A. (2008). Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. *Proc. Natl. Acad. Sci. USA* **105**, 1955-1959.
- Jarriault, S., Brou, C., Logeat, F., Schroeter, E. H., Kopan, R. and Israel, A. (1995). Signalling downstream of activated mammalian Notch. *Nature* **377**, 355-358.
- Jiang, X., Rowitch, D. H., Soriano, P., McMahon, A. P. and Sucov, H. M. (2000). Fate of the mammalian cardiac neural crest. *Development* **127**, 1607-1616.
- Li, X., Zhang, X., Leathers, R., Makino, A., Huang, C., Parsa, P., Macias, J., Yuan, J. X.-J., Jamieson, S. W. and Thistlethwaite, P. A. (2009). Notch3 signaling promotes the development of pulmonary arterial hypertension. *Nat. Med.* **15**, 1289-1297.
- Li, Y., Hibbs, M. A., Gard, A. L., Shylo, N. A. and Yun, K. (2012). Genome-wide analysis of N1ICD/RBPJ targets in vivo reveals direct transcriptional regulation of Wnt, SHH, and Hippo pathway effectors by Notch1. *Stem Cells* **30**, 741-752.
- Li, Y.-W., Shen, H., Frangou, C., Yang, N., Guo, J., Xu, B., Bshara, W., Shepherd, L., Zhu, Q., Wang, J. et al. (2015). Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. *Cell Cycle* **14**, 146-156.
- Madisen, L., Zwingman, T. A., Sunken, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R. et al. (2010). A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* **13**, 133-140.
- Makita, R., Uchijima, Y., Nishiyama, K., Amano, T., Chen, Q., Takeuchi, T., Mitani, A., Nagase, T., Yatomi, Y., Aburatani, H. et al. (2008). Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. *Am. J. Physiol. Renal Physiol.* **294**, F542-F553.
- Manderfield, L. J., High, F. A., Engleka, K. A., Liu, F., Li, L., Rentschler, S. and Epstein, J. A. (2012). Notch activation of Jagged1 contributes to the assembly of the arterial wall. *Circulation* **125**, 314-323.
- Manderfield, L. J., Engleka, K. A., Aghajanian, H., Gupta, M., Yang, S., Li, L., Baggs, J. E., Hogenesch, J. B., Olson, E. N. and Epstein, J. A. (2014). Pax3 and Hippo signaling coordinate melanocyte gene expression in neural crest. *Cell Rep.* **9**, 1885-1895.
- Mead, T. J. and Yutzey, K. E. (2012). Notch pathway regulation of neural crest cell development in vivo. *Dev. Dyn.* **241**, 376-389.
- Mo, J.-S., Park, H. W. and Guan, K.-L. (2014). The Hippo signaling pathway in stem cell biology and cancer. *EMBO Rep.* **15**, 642-656.
- Murakami, M., Nakagawa, M., Olson, E. N. and Nakagawa, O. (2005). A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome. *Proc. Natl. Acad. Sci. USA* **102**, 18034-18039.
- Neto-Silva, R. M., de Beco, S. and Johnston, L. A. (2010). Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the *Drosophila* homolog of Yap. *Dev. Cell* **19**, 507-520.
- Oka, T., Mazack, V. and Sudol, M. (2008). Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). *J. Biol. Chem.* **283**, 27534-27546.
- Rayon, T., Menchero, S., Nieto, A., Xenopoulos, P., Crespo, M., Cockburn, K., Cañon, S., Sasaki, H., Hadjantonakis, A.-K., de la Pompa, J. L. et al. (2014). Notch and Hippo converge on Cdx2 to specify the trophectoderm lineage in the mouse blastocyst. *Dev. Cell* **30**, 410-422.
- Robinson, D. R., Kalyana-Sundaram, S., Wu, Y.-M., Shankar, S., Cao, X., Ateeq, B., Asangani, I. A., Iyer, M., Maher, C. A., Grasso, C. S. et al. (2011). Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. *Nat. Med.* **17**, 1646-1651.
- Russ, W. P., Lowery, D. M., Mishra, P., Yaffe, M. B. and Ranganathan, R. (2005). Natural-like function in artificial WW domains. *Nature* **437**, 579-583.
- Strano, S., Munarriz, E., Rossi, M., Castagnoli, L., Shaul, Y., Sacchi, A., Oren, M., Sudol, M., Cesareni, G. and Blandino, G. (2001). Physical interaction with Yes-associated protein enhances p73 transcriptional activity. *J. Biol. Chem.* **276**, 15164-15173.
- Stylianou, S., Clarke, R. B. and Brennan, K. (2006). Aberrant activation of notch signaling in human breast cancer. *Cancer Res.* **66**, 1517-1525.
- Taniguchi, K., Wu, L.-W., Grivennikov, S. I., de Jong, P. R., Lian, I., Yu, F.-X., Wang, K., Ho, S. B., Boland, B. S., Chang, J. T. et al. (2015). A gp130–Src–YAP module links inflammation to epithelial regeneration. *Nature* **519**, 57-62.
- Tschaharganeh, D. F., Chen, X., Latzko, P., Malz, M., Gaida, M. M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N. et al. (2013). Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. *Gastroenterology* **144**, 1530-1542.e12.
- Varelas, X. (2014). The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. *Development* **141**, 1614-1626.
- Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., Rodriguez-Carunchio, L., Solé, M., Thung, S., Stanger, B. Z. et al. (2012). Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. *Gastroenterology* **143**, 1660-1669.e7.
- von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. N., Ma, Q., Ishiwata, T., Zhou, B., Camargo, F. D. et al. (2012). YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. *Proc. Natl. Acad. Sci. USA* **109**, 2394-2399.
- Wang, X., Hu, G., Gao, X., Wang, Y., Zhang, W., Harmon, E. Y., Zhi, X., Xu, Z., Lennartz, M. R., Barroso, M. et al. (2012). The induction of yes-associated protein expression after arterial injury is crucial for smooth muscle phenotypic

- modulation and neointima formation. *Arterioscler. Thromb. Vasc. Biol.* **32**, 2662-2669.
- Wang, Y., Hu, G., Liu, F., Wang, X., Wu, M., Schwarz, J. J. and Zhou, J. (2014). Deletion of yes-associated protein (YAP) specifically in cardiac and vascular smooth muscle cells reveals a crucial role for YAP in mouse cardiovascular development. *Circ. Res.* **114**, 957-965.
- Weng, A. P., Millholland, J. M., Yashiro-Ohtani, Y., Arcangeli, M. L., Lau, A., Wai, C., Del Bianco, C., Rodriguez, C. G., Sai, H., Tobias, J. et al. (2006). c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. *Genes Dev.* **20**, 2096-2109.
- Xie, C., Guo, Y., Zhu, T., Zhang, J., Ma, P. X. and Chen, Y. E. (2012). Yap1 protein regulates vascular smooth muscle cell phenotypic switch by interaction with myocardin. *J. Biol. Chem.* **287**, 14598-14605.
- Xin, M., Kim, Y., Sutherland, L. B., Qi, X., McAnally, J., Schwartz, R. J., Richardson, J. A., Bassel-Duby, R. and Olson, E. N. (2011). Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. *Sci. Signal.* **4**, ra70.
- Xin, M., Kim, Y., Sutherland, L. B., Murakami, M., Qi, X., McAnally, J., Porrello, E. R., Mahmoud, A. I., Tan, W., Shelton, J. M. et al. (2013). Hippo pathway effector Yap promotes cardiac regeneration. *Proc. Natl. Acad. Sci. USA* **110**, 13839-13844.
- Yimlamai, D., Christodoulou, C., Galli, G. G., Yanger, K., Pepe-Mooney, B., Gurung, B., Shrestha, K., Cahan, P., Stanger, B. Z. and Camargo, F. D. (2014). Hippo pathway activity influences liver cell fate. *Cell* **157**, 1324-1338.
- Yu, F.-X., Zhang, Y., Park, H. W., Jewell, J. L., Chen, Q., Deng, Y., Pan, D., Taylor, S. S., Lai, Z.-C. and Guan, K.-L. (2013). Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. *Genes Dev.* **27**, 1223-1232.
- Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S.-T., Luk, J. M., Wigler, M., Hannon, G. J. et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. *Cell* **125**, 1253-1267.
- Zhao, B., Kim, J., Ye, X., Lai, Z.-C. and Guan, K.-L. (2009). Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. *Cancer Res.* **69**, 1089-1098.





**Figure S1. Yap/Taz neural crest null embryos display normal migration and patterning of cardiac neural crest.** (A) Transverse sections of E10.5 *Wnt1-Cre; Taz<sup>flox/+</sup>; Yap<sup>flox/+</sup>; R26<sup>Tom/+</sup>* embryos stained for tdTomato (RFP). (B) Transverse sections of E10.5 *Wnt1-Cre; Taz<sup>flox/flox</sup>; Yap<sup>flox/flox</sup>; R26<sup>Tom/+</sup>* embryos stained for tdTomato (RFP). Both series of images begin at the mandibular component of the first arch artery (i), progress through the aortic sac (Ao), the outflow tract (OFT) and end at the developing heart (A=atria, V=ventricle). Scale bar (located in last image of each series, same for all images): 100 μm.



**Figure S2. Yap/Taz neural crest null embryos display no alterations in proliferation.**

(A-D) Transverse sections of E10.5 *Wnt1-Cre; Taz<sup>flox/+</sup>; Yap<sup>flox/+</sup>; R26<sup>Tom/+</sup>* embryos stained for tdTomato (RFP) and phospho-histone H3 (pHH3) as a marker of proliferation (A), RFP (B), pHH3 (C) or merged RFP/pHH3 (D). (E-H) Transverse sections of E10.5 *Wnt1-Cre; Taz<sup>flox/flox</sup>; Yap<sup>flox/flox</sup>; R26<sup>Tom/+</sup>* embryos stained for tdTomato (RFP) and phospho-histone H3 (pHH3) as a marker of proliferation (E), RFP (F), pHH3 (G) or merged RFP/pHH3 (H). Yellow arrows indicate co-positive RFP/pHH3 cells. Images were merged by combining respective red and green channels using Photoshop software (Adobe, A, D, E, H). Scale bars: 100  $\mu$ m.



**Table S1**

Figure 4A: ANOVA, Tukey-Kramer Multiple Comparisons Test Results

Comparison	Mean Difference	q	P value
-/- vs NICD/-/-	-2.449	2.474	ns P>0.05
-/- vs Yap/-/-	-7.968	8.049	*** P<0.001
-/- vs NICD/Yap/-	-16.500	16.668	*** P<0.001
-/- vs DNTEAD1/-/-	0.08508	0.08595	ns P>0.05
-/- vs NICD/DNTEAD1/-	-1.870	1.890	ns P>0.05
-/- vs Yap/DNTEAD1/-	-6.909	6.980	** P<0.01
-/- vs NICD/Yap/DNTEAD1	-14.632	14.782	*** P<0.001
NICD/-/- vs Yap/-/-	-5.518	5.575	* P>0.05
NICD/-/- vs NICD/Yap/-	-14.051	14.194	*** P<0.001
NICD/-/- vs DNTEAD1/-/-	2.534	2.560	ns P>0.05
NICD/-/- vs NICD/DNTEAD1/-	0.5788	0.5847	ns P>0.05
NICD/-/- vs Yap/DNTEAD1/-	-4.460	4.505	ns P>0.05
NICD/-/- vs NICD/Yap/DNTEAD1	-12.183	12.307	*** P<0.001
Yap/-/- vs NICD/Yap/-	-8.532	8.619	*** P<0.001
Yap/-/- vs DNTEAD1/-/-	8.053	8.153	*** P<0.001
Yap/-/- vs NICD/DNTEAD1/-	6.097	6.159	** P<0.01
Yap/-/- vs Yap/DNTEAD1/-	1.058	1.069	ns P>0.05
Yap/-/- vs NICD/Yap/DNTEAD1	-6.665	6.733	** P<0.01
NICD/Yap/- vs DNTEAD1/-/-	16.585	16.754	*** P<0.001
NICD/Yap/- vs NICD/DNTEAD1/-	14.630	14.779	*** P<0.001
NICD/Yap/- vs Yap/DNTEAD1/-	9.591	9.688	*** P<0.001
NICD/Yap/- vs NICD/Yap/DNTEAD1	1.868	1.887	ns P>0.05
DNTEAD1/-/- vs NICD/DNTEAD1/-	-1.956	1.975	ns P>0.05
DNTEAD1/-/- vs Yap/DNTEAD1/-	-6.994	7.066	** P<0.01
DNTEAD1/-/- vs NICD/Yap/DNTEAD1	-14.718	14.868	*** P<0.001
NICD/DNTEAD1/- vs Yap/DNTEAD1/-	-5.039	5.090	* P<0.05
NICD/DNTEAD1/- vs NICD/Yap/DNTEAD1	-12.762	12.892	*** P<0.001
Yap/DNTEAD1/- vs NICD/Yap/DNTEAD1	-7.723	7.802	*** P<0.001

**Table S2**

Figure 4C: ANOVA, Tukey-Kramer Multiple Comparisons Test Results

Comparison	Mean Difference	q	P value
-/-/- vs NICD/-/-	-2.456	4.260	ns P>0.05
-/-/- vs Yap/-/-	-8.952	15.528	*** P<0.001
-/-/- vs NICD/Yap/-	-17.750	30.788	*** P<0.001
-/-/- vs DNTEAD1/-/-	0.3881	0.6732	ns P>0.05
-/-/- vs NICD/DNTEAD1/-	-1.245	2.160	ns P>0.05
-/-/- vs Yap/DNTEAD1/-	-6.616	11.476	*** P<0.001
-/-/- vs NICD/Yap/DNTEAD1	-12.511	21.701	*** P<0.001
NICD/-/- vs Yap/-/-	-6.496	11.268	*** P<0.001
NICD/-/- vs NICD/Yap/-	-15.294	26.528	*** P<0.001
NICD/-/- vs DNTEAD1/-/-	2.844	4.933	* P<0.05
NICD/-/- vs NICD/DNTEAD1/-	1.210	2.100	ns P>0.05
NICD/-/- vs Yap/DNTEAD1/-	-4.160	7.216	** P<0.01
NICD/-/- vs NICD/Yap/DNTEAD1	-10.055	17.441	*** P<0.001
Yap/-/- vs NICD/Yap/-	-8.798	15.260	*** P<0.001
Yap/-/- vs DNTEAD1/-/-	9.340	16.201	*** P<0.001
Yap/-/- vs NICD/DNTEAD1/-	7.707	13.368	*** P<0.001
Yap/-/- vs Yap/DNTEAD1/-	2.336	4.053	ns P>0.05
Yap/-/- vs NICD/Yap/DNTEAD1	-3.559	6.173	** P<0.01
NICD/Yap/- vs DNTEAD1/-/-	18.138	31.461	*** P<0.001
NICD/Yap/- vs NICD/DNTEAD1/-	16.505	28.628	*** P<0.001
NICD/Yap/- vs Yap/DNTEAD1/-	11.134	19.313	*** P<0.001
NICD/Yap/- vs NICD/Yap/DNTEAD1	5.239	9.087	*** P<0.001
DNTEAD1/-/- vs NICD/DNTEAD1/-	-1.634	2.833	ns P>0.05
DNTEAD1/-/- vs Yap/DNTEAD1/-	-7.004	12.149	*** P<0.001
DNTEAD1/-/- vs NICD/Yap/DNTEAD1	-12.899	22.374	*** P<0.001
NICD/DNTEAD1/- vs Yap/DNTEAD1/-	-5.370	9.315	*** P<0.001
NICD/DNTEAD1/- vs NICD/Yap/DNTEAD1	-11.266	19.541	*** P<0.001
Yap/DNTEAD1/- vs NICD/Yap/DNTEAD1	-5.895	10.226	*** P<0.001



**Table S3**

Figure 4D: ANOVA, Tukey-Kramer Multiple Comparisons Test Results

Comparison	Mean Difference	q	P value
Mst1/-/- vs NICD/Mst1/-	-2.863	0.6144	ns P>0.05
Mst1/-/- vs Yap/Mst1/-	-1.931	0.4143	ns P>0.05
Mst1/-/- vs NICD/Yap/Mst1	-5.084	1.091	ns P>0.05
Mst1/-/- vs NICD/Yap/-	-39.241	8.419	*** P<0.001
Mst1/-/- vs Mst1-KI/-/-	-2.396	0.5140	ns P>0.05
Mst1/-/- vs NICD/Mst1-KI/-	-8.509	1.825	ns P>0.05
Mst1/-/- vs Yap/Mst1-KI/-	-31.565	6.771	** P<0.01
Mst1/-/- vs NICD/Yap/Mst1-KI	-41.470	8.897	*** P<0.001
NICD/Mst1/- vs Yap/Mst1/-	0.9323	0.2000	ns P>0.05
NICD/Mst1/- vs NICD/Yap/Mst1	-2.220	0.4763	ns P>0.05
NICD/Mst1/- vs NICD/Yap/-	-36.378	7.805	*** P<0.001
NICD/Mst1/- vs Mst1-KI/-/-	0.4678	0.1004	ns P>0.05
NICD/Mst1/- vs NICD/Mst1-KI/-	-5.645	1.211	ns P>0.05
NICD/Mst1/- vs Yap/Mst1-KI/-	-28.701	6.158	** P<0.01
NICD/Mst1/- vs NICD/Yap/Mst1-KI	-38.607	8.283	*** P<0.001
Yap/Mst1/- vs NICD/Yap/Mst1	-3.152	0.6763	ns P>0.05
Yap/Mst1/- vs NICD/Yap/-	-37.310	8.005	*** P<0.001
Yap/Mst1/- vs Mst1-KI/-/-	-0.4645	0.9965	ns P>0.05
Yap/Mst1/- vs NICD/Mst1-KI/-	-6.577	1.411	ns P>0.05
Yap/Mst1/- vs Yap/Mst1-KI/-	-29.634	6.358	** P<0.01
Yap/Mst1/- vs NICD/Yap/Mst1-KI	-39.539	8.483	*** P<0.001
NICD/Yap/Mst1 vs NICD/Yap/-	-34.158	7.328	** P<0.01
NICD/Yap/Mst1 vs Mst1-KI/-/-	2.688	0.5767	ns P>0.05
NICD/Yap/Mst1 vs NICD/Mst1-KI/-	-3.425	0.7348	ns P>0.05
NICD/Yap/Mst1 vs Yap/Mst1-KI/-	-26.481	5.681	* P<0.05
NICD/Yap/Mst1 vs NICD/Yap/Mst1-KI	-36.387	7.807	*** P<0.001
NICD/Yap/- vs Mst1-KI/-/-	36.845	7.905	*** P<0.001
NICD/Yap/- vs NICD/Mst1-KI/-	30.732	6.594	** P<0.01
NICD/Yap/- vs Yap/Mst1-KI/-	7.676	1.647	ns P>0.05
NICD/Yap/- vs NICD/Yap/Mst1-KI	-2.229	0.4782	ns P>0.05
Mst1-KI/-/- vs NICD/Mst1-KI/-	-6.113	1.312	ns P>0.05
Mst1-KI/-/- vs Yap/ Mst1-KI/-	-29.169	6.258	** P<0.01
Mst1-KI/-/- vs NICD/Yap/Mst1-KI	-39.074	8.383	*** P<0.001
NICD/Mst1-KI/- vs Yap/Mst1-KI/-	-23.056	4.947	ns P>0.05
NICD/Mst1-KI/- vs NICD/Yap/Mst1-KI	-32.961	7.072	** P<0.01
Yap/Mst1-KI/- vs NICD/Yap/Mst1-KI	-9.905	2.125	ns P>0.05

**Table S4**

Figure 6A: ANOVA, Tukey–Kramer Multiple Comparisons Test Results

Comparison	Mean Difference	q	P value
-/- vs NICD/-	-8.353	1.144	ns P>0.05
-/- vs Yap/-	-28.897	3.958	ns P>0.05
-/- vs YapWW1/-	-15.530	2.217	ns P>0.05
-/- vs YapWW2/-	-34.967	4.789	* P<0.05
-/- vs YapWW1WW2/-	-15.999	2.191	ns P>0.05
-/- vs NICD/Yap	-59.762	8.185	*** P<0.001
-/- vs NICD/YapWW1	-17.164	2.351	ns P>0.05
-/- vs NICD/YapWW2	-62.327	8.536	*** P<0.001
-/- vs NICD/YapWW1WW2	-32.259	4.418	ns P>0.05
NICD/- vs Yap/-	-20.544	2.814	ns P>0.05
NICD/- vs YapWW1/-	-7.177	0.9829	ns P>0.05
NICD/- vs YapWW2/-	-26.614	3.645	ns P>0.05
NICD/- vs YapWW1WW2/-	-7.646	1.047	ns P>0.05
NICD/- vs NICD/Yap	-51.409	7.041	*** P<0.001
NICD/- vs NICD/YapWW1	-8.811	1.207	ns P>0.05
NICD/- vs NICD/YapWW2	-53.974	7.392	*** P<0.001
NICD/- vs NICD/YapWW1WW2	-23.906	3.274	ns P>0.05
Yap/- vs YapWW1/-	13.367	1.831	ns P>0.05
Yap/- vs YapWW2/-	-6.070	0.8314	ns P>0.05
Yap/- vs YapWW1WW2/-	12.898	1.766	ns P>0.05
Yap/- vs NICD/Yap	-30.866	4.227	ns P>0.05
Yap/- vs NICD/YapWW1	11.732	1.607	ns P>0.05
Yap/- vs NICD/YapWW2	-33.431	4.578	ns P>0.05
Yap/- vs NICD/YapWW1WW2	-3.363	0.4605	ns P>0.05
YapWW1/- vs YapWW2/-	-19.437	2.662	ns P>0.05
YapWW1/- vs YapWW1WW2/-	-0.4687	0.06420	ns P>0.05
YapWW1/- vs NICD/Yap	-44.232	6.058	** P<0.01
YapWW1/- vs NICD/YapWW1	-1.634	0.2238	ns P>0.05
YapWW1/- vs NICD/YapWW2	-46.797	6.409	** P<0.01
YapWW1/- vs NICD/YapWW1WW2	-16.729	2.291	ns P>0.05
YapWW2/- vs YapWW1WW2/-	18.968	2.598	ns P>0.05
YapWW2/- vs NICD/Yap	-24.795	3.396	ns P>0.05
YapWW2/- vs NICD/YapWW1	17.803	2.428	ns P>0.05
YapWW2/- vs NICD/YapWW2	-27.360	3.747	ns P>0.05
YapWW2/- vs NICD/YapWW1WW2	2.708	0.3708	ns P>0.05
YapWW1WW2/- vs NICD/Yap	-43.764	5.994	** P<0.01
YapWW1WW2/- vs NICD/YapWW1	-1.165	0.1596	ns P>0.05
YapWW1WW2/- vs NICD/YapWW2	-46.328	6.345	** P<0.01
YapWW1WW2/- vs NICD/YapWW1WW2	-16.261	2.227	ns P>0.05
NICD/Yap vs NICD/YapWW1	42.598	5.834	** P<0.01
NICD/Yap vs NICD/YapWW2	-2.565	0.3513	ns P>0.05
NICD/Yap vs NICD/YapWW1WW2	27.503	3.767	ns P>0.05
NICD/YapWW1 vs NICD/YapWW2	-45.163	6.185	** P<0.01
NICD/YapWW1 vs NICD/YapWW1WW2	-15.095	2.067	ns P>0.05
NICD/YapWW2 vs NICD/YapWW1WW2	30.068	4.118	ns P>0.05

**Table S5.** Quantitative RT-PCR primer sequences

<i>cmyc</i> Forward	5' CTGTTTGAAGGCTGGATTTCCT 3'
<i>cmyc</i> Reverse	5' CAGCACCGACAGACGCC 3'
<i>Hrt1</i> Forward	5' TTGTCAACACCACCCTAAAGTCG 3'
<i>Hrt1</i> Reverse	5' CACCTCGGTCCATCAAAGTAGTAAC 3'
<i>Hrt2</i> Forward	5' GTAAGTATGTCGTCCATTTTCGG 3'
<i>Hrt2</i> Reverse	5' TGCCTGCTTCTTCTCTTTCTCAAC 3'
<i>Hrt3</i> Forward	5' TTCAGAAAAGTGGAACAGAGGGC 3'
<i>Hrt3</i> Reverse	5' CCAATCAGGATGGATGCTCAAAG 3'
<i>Jagged1</i> Forward	5' GCTTCCACTGGCACTGGTAGTTTC 3'
<i>Jagged1</i> Reverse	5' TGCTGACATCAAATCCCCCCTC 3'
<i>Tagln</i> Forward	5' CAACAAGGGTCCATCCTACGG 3'
<i>Tagln</i> Reverse	5' ATCTGGGCGGCCTACATCA 3'
<i>Acta2</i> Forward	5' GTCCCAGACATCAGGGAGTAA 3'
<i>Acta2</i> Reverse	5' TCGGATACTTCAGCGTCAGGA 3'
<i>Cnn1</i> Forward	5' AAACAAGAGCGGAGATTGAGC 3'
<i>Cnn1</i> Reverse	5' TGTCGCAGTGTTCCATGCC 3'
<i>Des1</i> Forward	5' GAGCTGGAGGATCGCTTTG 3'
<i>Des1</i> Reverse	5' GAAGGTCTGGATAGGAAGGTTGA 3'
<i>Gapdh</i> Forward	5' CGTCCCGTAGACAAAATGGT 3'
<i>Gapdh</i> Reverse	5' GAATTTGCCGTGAGTGGAGT 3'